Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.

In this study, we investigated the yeasts colonization of genus Candida, including C. dubliniensis, isolated of HIV-infected patients oral cavities and we accessed in vitro susceptibility pattern of the Candida isolates to four antifungal agents. Out of 99 patients investigated, 62 (62.6%) were colonized with yeasts. C. albicans was the prevailing species (50%). C. dubliniensis isolates were not recovered in our study. We verified that 8.1% of the yeasts isolated were resistant to fluconazole, 8.1% to itraconazole and 3.2% to voriconazole. The isolates demonstrated very low voriconazole MICs, in which 79% (49/62) presented values of 0.015 mug/ml. All Candida isolates were susceptible to amphotericin B. The results reported here showed that although C. albicans continues to be present in one-half of oral Candida carriage of HIV-infected patients, Candida non-albicans species are increasing among these patients. Besides, the findings of resistant isolates endorse the role of antifungal susceptibility testing whenever antifungal treatment with azoles is planned.

Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.

We evaluated the antifungal activities of amphotericin B, fluconazole, itraconazole and voriconazole in 70 Cryptococcus neoformans strains obtained from cerebrospinal fluid from AIDS patients and 40 C. neoformans strains isolated from the environment. Four clinical isolates were identified as C. neoformans var. gattii. The susceptibility test was done using a broth microdilution method according to NCCLS M27-A2. Range minimal inhibitory concentrations (MICs) for C. neoformans clinical isolates were 0.06-1.0 microg/mL for amphotericin B, 0.125-8 microg/mL for fluconazole, 0.03-0.5 microg/mL for itraconazole and 0.03-0.25 microg/mL for voriconazole. C. neoformans environmental isolates showed range MICs 0.015-0.125 microg/mL, 0.25-2.0 microg/mL, 0.007-0.125 microg/mL and 0.03-0.25 microg/mL for amphotericin B, fluconazole, itraconazole and voriconazole respectively. The MICs results obtained from clinical and environmental isolates showed similar pattern of susceptibility and no resistance has been found in our isolates.

Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in goiânia city, Goiás, Brasil

A atividade antifúngica de anfotericina B, fluconazol, itraconazol e voriconazol foi avaliada em 70 amostras de Cryptococcus neoformans isoladas de liquido céfalo raquidiano (LCR) de pacientes com AIDS e em 40 amostras de C. neoformans obtidas do meio ambiente. Dentre os isolados 66 foram identificados como C. neoformans var. neoformans e quatro isolados clínicos, como C. neoformans var. gattii. Para a realização dos testes de suscetibilidade foi utilizado o método de microdiluição em meio líquido segundo o NCCLS M27-A2. As concentrações inibitórias mínimas (CIMs) para os isolados clínicos variaram de 0,06-1,0 µg/mL para anfotericina B, 0,125-8 µg/mL para fluconazol, 0,03-0,5 µg/mL para itraconazol e 0,03-0,25 µg/mL para voriconazol, enquanto que para as amostras ambientais de C. neoformans as concentrações inibitórias variaram de 0,015-0,125 µg/mL, 0,25-2,0 µg/mL, 0,007-0,125 µg/mL e 0,03-0,25 µg/mL para anfotericina B, fluconazol, itraconazol e voriconazol, respectivamente. Os resultados das concentrações inibitórias mínimas obtidas para os isolados clínicos e ambientais mostraram semelhança com relação ao perfil de suscetibilidade, não tendo sido encontrados isolados resistentes a nenhum dos antifúngicos, levando-se em consideração a metodologia e critério de interpretação estudados.